- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Effector Therapeutics Inc (EFTR)
Effector Therapeutics Inc stock price live, this page displays OTC EFTR stock exchange data. View the EFTR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Effector Therapeutics Inc real time stock price chart below.
What Is the Effector Therapeutics Inc Stock Price Today?
The Effector Therapeutics Inc stock price today is 0.001.
What Is the Stock Symbol for Effector Therapeutics Inc?
The stock symbol for Effector Therapeutics Inc is ""EFTR.""
What Stock Exchange Does Effector Therapeutics Inc Trade On?
Effector Therapeutics Inc is listed and trades on the OTC Markets stock exchange.
Is Effector Therapeutics Inc a Good Stock to Buy?
Determining whether Effector Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EFTR quote. (ISIN: US28202V2079)
What Is the Effector Therapeutics Inc Stock Price Today?
The Effector Therapeutics Inc stock price today is 0.001.
What Is the Stock Symbol for Effector Therapeutics Inc?
The stock symbol for Effector Therapeutics Inc is ""EFTR.""
What Stock Exchange Does Effector Therapeutics Inc Trade On?
Effector Therapeutics Inc is listed and trades on the OTC Markets stock exchange.
Is Effector Therapeutics Inc a Good Stock to Buy?
Determining whether Effector Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EFTR quote. (ISIN: US28202V2079)
OTC Markets
Currency in USD
0.001
0.000(0.00%)
Closed·
Fair Value
An estimate of a Locust Walk Acquisition's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.001
0.001
52 wk Range
0.001
0.060
EFTR Scorecard
Full Analysis
Stock generally trades with high price volatility
Trading near 52-week Low
More Info
Fair Value
An estimate of a Locust Walk Acquisition's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0010.001
52 wk Range
0.0010.060
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EFTR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Locust Walk Acquisition's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Locust Walk Acquisition Corp Company Profile
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Compare EFTR to Peers and Sector
Metrics to compare | EFTR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEFTRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −4.7x | −0.5x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 9.6x | 3.2x | |
Upside (Analyst Target) | 0.0% | 178.3% | 41.9% | |
Fair Value Upside | Unlock | 6.7% | 4.3% | Unlock |
Earnings
Latest Release
May 09, 2024
EPS / Forecast
-2.16 / -3.00
Revenue / Forecast
-- / --
FAQ
What Stock Exchange Does Locust Walk Acquisition Trade On?
Locust Walk Acquisition is listed and trades on the OTC Markets stock exchange.
What Is the Stock Symbol for Locust Walk Acquisition?
The stock symbol for Locust Walk Acquisition is "EFTR."
What Is the Locust Walk Acquisition Market Cap?
As of today, Locust Walk Acquisition market cap is 4.70K.
What Is Locust Walk Acquisition's Earnings Per Share (TTM)?
The Locust Walk Acquisition EPS (TTM) is -12.42.
From a Technical Analysis Perspective, Is EFTR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Locust Walk Acquisition Stock Split?
Locust Walk Acquisition has split 1 times.
How Many Employees Does Locust Walk Acquisition Have?
Locust Walk Acquisition has 14 employees.
What is the current trading status of Locust Walk Acquisition (EFTR)?
As of 24 Jul 2025, Locust Walk Acquisition (EFTR) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.06.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.